ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0045926;negative regulation of growth;4.0;0.5916390046238794;0.5458195023119397;7.3461418668155956;22.254552265759827;4.288135901523783;7.448398365382569E-4;0.4692954694226389;[BBS2, SEMA6B, CDKN1A, CDKN2C, IGFBP5, STK3, PPP2CA, FLCN, SERTAD3, SFRP1, GAL, NPPA, WWC3, MT1G]
GO:0006281;DNA repair;7.0;0.6281612110245125;0.6649999707694567;8.781226392104918;180.342582143442;3.582668236575797;0.006035903926554339;0.534137185486798;[USP36, FEN1, BTG2, SMG1, WDR48, DCLRE1C, CIB1, YY1, POLB, RAD51AP1, NIPBL, CHAF1B, CHAF1A, POLR2B, EXO1, RAD21, EP300, POLR2G, USP51, FANCI, UPF1, POLQ, AQR, UBE2B, FBXO18, DTX3L, NCOA6, EYA2, XRCC5, INTS3, GINS4, RAD23A, CDC7, GTF2H4, SETX, CDK9, DDB1, SMUG1, NEIL3, HIST3H2A, COPS5, RAD51C, RAD51, MSH3, UBE2T, POLE2, TIMELESS]
GO:0014068;positive regulation of phosphatidylinositol 3-kinase signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;5.602686357784832;0.007979625599047746;0.6615216408886768;[PDGFRB, BECN1, NCF1, CCL5]
GO:0008584;male gonad development;5.0;1.0;0.7902410118609202;9.628524252492122;50.96471695749156;5.2552850506314295;0.001705743211299806;0.5589965337459591;[PDGFRB, RRM1, SFRP1, RNF38, H3F3A, SOX8, MEA1]
GO:0007131;reciprocal meiotic recombination;9.0;1.0;0.896240625180289;9.628524252492122;175.07189671554147;6.343086423195323;0.005859498828591432;0.7206263598461826;[RAD51C, RAD51, MSH3, RAD21]
GO:0046854;phosphatidylinositol phosphorylation;8.0;1.0;0.875;9.628524252492122;218.7418113453505;5.049685808968129;0.007321091570879569;0.6332411671050352;[PDGFRB, SMG1, CD80, PIK3C3, VAV1, HBEGF]
GO:1900535;palmitic acid biosynthetic process;10.0;1.0;0.9152410118609203;9.628524252492122;557.4048334587134;8.390779266560578;0.018655838144081716;0.8443458537639685;[ACOT7]
GO:0032967;positive regulation of collagen biosynthetic process;6.0;1.0;0.8231203125901445;9.628524252492122;105.22247330055487;6.558197802812269;0.003521701487291661;0.6585068532133508;[PDGFRB, ITGA2]
GO:0052695;cellular glucuronidation;9.0;0.8653626801206646;0.8289219652406215;9.446202695698167;85.04062765322598;6.8867018697843045;0.0028462332759574376;0.7484268790654467;[UGT2B17, UGT2B7]
GO:0015709;thiosulfate transport;7.0;1.0;0.8509193652572005;9.628524252492122;30.347012514884874;8.390779266560578;0.0010156871983350835;0.7800242071602487;[SLC25A10]
GO:0051482;positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;292.0931097099921;6.139487467954083;0.009776093515261451;0.7620939872166814;[GPR55]
GO:0018279;protein N-linked glycosylation via asparagine;9.0;0.8653626801206646;0.8289219652406215;9.4949928598676;334.83267440717236;6.113511981550823;0.011206548282565083;0.7088859122241795;[DERL3, SYVN1]
GO:0019367;fatty acid elongation, saturated fatty acid;10.0;1.0;0.9152410118609203;9.628524252492122;363.0266052285773;7.8311634786251565;0.012150173774267114;0.8157270763441555;[ELOVL5, ELOVL6]
GO:0034626;fatty acid elongation, polyunsaturated fatty acid;11.0;1.0;0.9324289523296623;9.628524252492122;363.71975240913724;7.8311634786251565;0.012173372786608494;0.8329150168128974;[ELOVL5, ELOVL6]
GO:0019886;antigen processing and presentation of exogenous peptide antigen via MHC class II;5.0;1.0;0.7902410118609202;9.628524252492122;42.20009821028515;5.192106149009898;0.0014123993094755708;0.5557655617789146;[DCTN5, LAG3, FCER1G, DCTN4, CLTA, KLC1, DYNLL2, KIF15, CENPE, HLA-DMA, HLA-DMB, AP1G1, HLA-DPB1, AP2S1, KIF2C, CTSE, HLA-DRB3, SEC24C, HLA-DQA1, HLA-DPA1]
GO:0034625;fatty acid elongation, monounsaturated fatty acid;11.0;1.0;0.9324289523296623;9.628524252492122;363.71975240913724;7.8311634786251565;0.012173372786608494;0.8329150168128974;[ELOVL5, ELOVL6]
GO:0035435;phosphate ion transmembrane transport;8.0;0.8933024483968273;0.8216512241984136;9.485423408851448;110.11210983553856;7.138016298065211;0.003685353221730381;0.7400384854347593;[SLC25A3, SLC37A1, SLC25A10]
GO:0030148;sphingolipid biosynthetic process;7.0;0.6913464685778243;0.6965925995461126;8.992535485772125;238.8284648682076;5.288437257948329;0.007993373787475071;0.6213702925661609;[UGT8, SGPL1, ELOVL5, SPHK2, SPHK1, DEGS1, ELOVL6, SGPP2]
GO:2000491;positive regulation of hepatic stellate cell activation;6.0;1.0;0.8231203125901445;9.628524252492122;58.82470762909909;8.390779266560578;0.001968810025546158;0.7522251544931926;[PDGFRB]
GO:0035793;positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway;11.0;1.0;0.9324289523296623;9.628524252492122;462.90611455550015;8.67846133901236;0.015493051065716704;0.8762458687964789;[PDGFRB]
GO:0036120;cellular response to platelet-derived growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;6.781341354126479;0.003262744749111514;0.6699184248047958;[PDGFRB, ERRFI1, MARS, ATP7A]
GO:0051260;protein homooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;4.056761851073058;0.00140677858073304;0.5305833023127396;[COLEC12, PKD2L1, NLRC4, CLYBL, GLS, SPAST, RXRA, RNF213, RIPK1, ECT2, BID, VASP, POLQ, PDCD6IP, KCND1, FCER1G, TOR1A, ATPIF1, EIF2AK3, KCTD5, MARCKS, ALDH5A1, RAD51, KCTD10, IMPDH2, KCTD14, CHMP4B, ALDOA]
GO:0042420;dopamine catabolic process;8.0;1.0;0.875;9.628524252492122;561.0959123607433;7.697632086000634;0.018779375233177315;0.7686572628545723;[MOXD1, COMT]
GO:0042421;norepinephrine biosynthetic process;8.0;1.0;0.875;9.628524252492122;472.6140365713203;7.9853141584524145;0.015817966479023615;0.7833693374183408;[MOXD1]
GO:0042542;response to hydrogen peroxide;5.0;0.9326813400603323;0.7565816818910864;9.541512875502493;79.2907140195247;5.09494240055625;0.0026537888412237636;0.5507966031644187;[SETX, PDGFRB, BECN1, IL6, SDC1, ECT2, RELA, EZH2]
GO:0006974;cellular response to DNA damage stimulus;4.0;0.5696777571895439;0.534838878594772;7.469040003138749;28.997869804256865;3.161008442547652;9.705326059599744E-4;0.4116541187538124;[USP36, FEN1, BTG2, CDKN1A, SMG1, WDR48, DCLRE1C, CIB1, MCM10, AATF, YY1, POLB, NIPBL, CHAF1B, CHAF1A, EXO1, CASP2, EP300, CTLA4, UPF1, AQR, TIPIN, FBXO18, DTX3L, NCOA6, RAD23A, TFIP11, DDB1, NEIL3, RAD51C, TFDP2, MSH3, DDIT4, TIMELESS, TANK, RAD51AP1, NUAK1, CCNB1, POLR2B, RBBP5, RAD21, POLR2G, USP51, BID, E2F7, E2F8, FANCI, POLQ, UBE2B, EYA2, XRCC5, INTS3, GINS4, CNOT10, CDC7, GTF2H4, SETX, CDK9, SMUG1, CNOT6, HIST3H2A, COPS5, RAD51, CNOT1, UBE2T, POLE2, BCL3, MNDA, CNOT8]
GO:0042148;strand invasion;7.0;0.8436909121759173;0.7727648213451592;9.456673995565463;149.0421272461911;7.8311634786251565;0.0049883058697239;0.7514054297404357;[RAD51C, RAD51]
GO:0006335;DNA replication-dependent nucleosome assembly;8.0;1.0;0.875;9.628524252492122;163.41517932017535;7.474488534686424;0.005469358987733092;0.7572456912631272;[CHAF1B, CHAF1A, IPO4]
GO:0032956;regulation of actin cytoskeleton organization;7.0;0.559792591703537;0.630815661108969;7.718981747607684;34.11626247365944;3.9689311377000256;0.0011418406023505395;0.553890688213353;[MTPN, NCKAP1, WDR1, ROCK2, WIPF2, ARPC1A, IQGAP2, AKAP13, ARHGDIB, CFL1, PPFIA1, NCKAP1L, ARFIP1, CLASP1, VASP, PDGFRB, ACTR2, SSH3, SPTB, VIL1, SFRP1, ARPC2, FES, EPHA1, ARHGEF5]
GO:0045540;regulation of cholesterol biosynthetic process;9.0;0.8933024483968273;0.8428918493787028;9.4949928598676;116.98845768213258;6.039404009397101;0.0039154983958446;0.705096027081865;[SP1, NFYC, SCAP, ELOVL6, ERLIN2, KPNB1]
GO:0048015;phosphatidylinositol-mediated signaling;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;26.42836680105094;5.649939242635378;8.845336528452411E-4;0.6398575208746181;[PDGFRB, C1QBP, PIK3C3, SIRT2, EXOC1]
GO:0035789;metanephric mesenchymal cell migration;7.0;1.0;0.8509193652572005;9.628524252492122;22.41982222863266;9.777073627680469;7.503712734623007E-4;0.8509193652572005;[PDGFRB]
GO:0070317;negative regulation of G0 to G1 transition;7.0;1.0;0.8509193652572005;9.628524252492122;83.03241800612349;6.139487467954083;0.002779020306340262;0.6648930398837374;[RAD51, TFDP2, MAX, CDC7, EZH2]
GO:0036116;long-chain fatty-acyl-CoA catabolic process;8.0;1.0;0.875;9.628524252492122;360.0761283871993;9.083926447120524;0.012051423969642955;0.839552420951524;[ACOT7]
GO:0051897;positive regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;4.7664383335842135;0.007979625599047746;0.6187558780415471;[PDGFRB, IGFBP5, C1QBP, CD80, CCL19, THBS1, VAV1, STK3, HBEGF]
GO:0043406;positive regulation of MAP kinase activity;12.0;0.7043150770688792;0.8002778511245842;9.369013057007038;2605.6877929993507;4.201124524534153;0.08721002546492271;0.6629660161470909;[PDGFRB, MAP3K3, PDE6H, THBS1, ERN1, AKAP13, KARS, DVL3, RIPK1, CSK, KRAS, CCL19, ARHGEF5, EZH2]
GO:0035025;positive regulation of Rho protein signal transduction;10.0;1.0;0.9152410118609203;9.628524252492122;339.6245583269611;6.481236761676141;0.01136692832494487;0.7466917612613706;[PDGFRB, AKAP13, GPR55]
GO:0036114;medium-chain fatty-acyl-CoA catabolic process;8.0;1.0;0.875;9.628524252492122;359.38298120663484;9.083926447120524;0.012028224957301426;0.839552420951524;[ACOT7]
GO:0006260;DNA replication;7.0;0.7307253602413294;0.7162820453778652;9.271849308553389;254.20053156235352;4.77312732173501;0.008507863025766288;0.5950173184638491;[UPF1, POLQ, RRM1, FEN1, NCOA6, WRNIP1, MCM10, CDC7, BAZ1A, POLB, CHAF1B, CHAF1A, NFIB, EXO1, NFIC, POLE2, CDK2AP1, MCM2]
GO:0002181;cytoplasmic translation;8.0;1.0;0.875;9.628524252492122;403.65714686199146;5.825829909099042;0.013510041437624024;0.6729332124801218;[RPL22L1, RPL19]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[CDKN1A, WDR48, TFRC, ITGB3, CD80, SIRPG, CCNF, KIF14, CIB1, TIAL1, PPP1CC, LBH, FNTB, CTSH, SOX8, ATP7A, SKP2, CCR2, HLA-DPA1, PDGFRB, RPS9, TIPIN, CSNK2A1, IGFBP5, SPHK2, ITGA2, SPHK1, TBC1D8, ARNT, FLT3LG, PDCD1LG2, RUNX2, ERN1, SFRP1, CCNE2, IL23A, EPHA1, HBEGF, HDAC1, FOXG1, EBI3, DERL2, CRIP2, THBS1, RELA, CCNB1, HLA-DMB, CCL5, NCKAP1L, CCL19, TBX1, MAP3K3, CDC7, TSHR, CNOT6, CD4, IL6, SP1, HLA-DPB1, KRAS, CNOT8, CCNJL]
GO:0006024;glycosaminoglycan biosynthetic process;6.0;0.7586651285174919;0.7024528768488905;9.158520623246385;237.49504005673018;5.16195311083921;0.007948745259039342;0.5871028347338303;[PDGFRB, ABCC5, SLC35D2, SDC1]
GO:0008202;steroid metabolic process;4.0;0.566269677792466;0.5331348388962329;7.508260716292031;35.315100643705854;4.247644540169047;0.001181964637017687;0.4672247393199168;[HSD3B7, OSBPL2, HSD17B4, UGT2B17, ERLIN2, COMT, HSD17B8, SGPL1, RXRA, ACOX2, SNX17, SCAP, APOL1, SCARF1, SLC27A2, NFE2L1, UGT2B7]
GO:0038091;positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway;10.0;1.0;0.9152410118609203;9.628524252492122;112.44183520208205;8.67846133901236;0.0037633270331318856;0.8590579283277371;[PDGFRB]
GO:0071280;cellular response to copper ion;6.0;1.0;0.8231203125901445;9.628524252492122;78.50383844342444;6.518977089658987;0.0026274528238337297;0.6565011041187423;[BECN1, MT1G, ATP7A]
GO:0070192;chromosome organization involved in meiotic cell cycle;5.0;0.7043150770688792;0.6423985503953599;8.567652291806858;44.78603005185074;5.682729065458369;0.0014989481210252074;0.5808560405423884;[RAD51C, RAD51, UBE2B, CCNE2, BUB1B, SMC2]
GO:0006268;DNA unwinding involved in DNA replication;8.0;0.8259837884571596;0.7879918942285797;9.34084218004034;24.41922106263308;7.57984905034425;8.172893530941673E-4;0.7626338329336335;[RAD51, MCM2]
GO:0048661;positive regulation of smooth muscle cell proliferation;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;63.45804869205661;5.433268205826786;0.002123883781187112;0.6009779013089371;[ERN1, PDGFRB, IL6, IGFBP5, ITGA2, CCL5, SKP2, THBS1, HBEGF]
GO:0000165;MAPK cascade;9.0;0.7436939687323844;0.7680876095464813;9.236482164716097;231.45054935470895;4.069963362931594;0.007746441594931149;0.6043787408332628;[PDGFRB, MAP3K3, OXTR, KSR1, IL5RA, GFRA2, SPTB, RASGRP4, NFKB1, SETX, KARS, PABPN1, PTPRA, TNIP2, CCL5, CTSH, NCAM1, CCM2, MBP, RIPK1, KRAS, CALM1, HBEGF]
GO:0071670;smooth muscle cell chemotaxis;7.0;1.0;0.8509193652572005;9.628524252492122;55.63348935964576;9.083926447120524;0.0018620028219775377;0.8154717862087246;[PDGFRB]
GO:0030889;negative regulation of B cell proliferation;9.0;1.0;0.896240625180289;9.628524252492122;506.3396801226706;7.004484905440688;0.016946733417578675;0.7544503089863854;[CTLA4, MNDA]
GO:0070221;sulfide oxidation, using sulfide:quinone oxidoreductase;5.0;1.0;0.7902410118609202;9.628524252492122;32.98564573496375;7.9853141584524145;0.0011039998775953985;0.6986103492792611;[SLC25A10, SUOX]
GO:0046641;positive regulation of alpha-beta T cell proliferation;10.0;0.8653626801206646;0.8479223519212526;9.54628615425515;937.8544877713971;6.8867018697843045;0.03138914569146771;0.7674272657460779;[IL23A, EBI3, CCR2]
GO:0048146;positive regulation of fibroblast proliferation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;63.74573076450893;5.825829909099042;0.0021335122412550348;0.6210535250702663;[PDGFRB, CDKN1A, CCNB1, SPHK1, FNTB]
GO:0045671;negative regulation of osteoclast differentiation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;842.5336305879634;6.481236761676141;0.028198842384740134;0.7276913745807394;[SFRP1, GPR55, LILRB3]
GO:1990426;mitotic recombination-dependent replication fork processing;10.0;1.0;0.9152410118609203;9.628524252492122;328.81961107458824;9.083926447120524;0.011005296464229153;0.8797934328124444;[RAD51]
GO:0071276;cellular response to cadmium ion;6.0;1.0;0.8231203125901445;9.628524252492122;78.50383844342444;6.139487467954083;0.0026274528238337297;0.6370939872166814;[NCF1, MT1G, ATP7A]
GO:0070106;interleukin-27-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;7.379178354882098;0.00101047745553359;0.728290889492758;[EBI3]
GO:2000379;positive regulation of reactive oxygen species metabolic process;6.0;0.7763722522362496;0.7113064387082693;9.253830803050711;112.71770282919289;5.299736813202263;0.0037725600743465397;0.5941490996802742;[PDGFRB, CDKN1A, ITGB2, PTX3, RIPK1, THBS1]
GO:0050853;B cell receptor signaling pathway;10.0;0.9326813400603323;0.8815816818910864;9.582004236857228;219.43154282413207;4.948759890378168;0.007344176262756358;0.6683208227957298;[CTLA4, NCKAP1L, MNDA]
GO:0006270;DNA replication initiation;7.0;0.7980440201809971;0.7499413753476991;9.405380701177911;149.0421272461911;6.343086423195323;0.0049883058697239;0.6753050999230941;[CCNE2, GINS4, MCM10, CDC7, MCM2]
GO:0031295;T cell costimulation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;354.8971974647038;5.845247994956144;0.011878089812402261;0.6951668794741764;[CD80, CTLA4, CSK, PDCD1, PDCD1LG2, CCL19, VAV1]
GO:0007088;regulation of mitotic nuclear division;7.0;0.5860072649471136;0.6439229977307573;8.169909229792605;54.97351338155213;4.573066940603674;0.0018399140199305624;0.5847862212690335;[BECN1, CCNF, BUB1B, PKMYT1, ANAPC11, NIPBL, CCNB1, CDC26, RAD21, TPR, NUP62, FBXO5, PDGFRB, MAD2L1BP, NDC80, SIRT2, NSFL1C, CENPE, CENPF, STAG2, ESPL1, CCNE2, CHMP4B, ANAPC5, CCNJL, MAD2L1]
GO:0000727;double-strand break repair via break-induced replication;10.0;1.0;0.9152410118609203;9.628524252492122;521.7226431472901;8.16763571524637;0.01746158734624478;0.8329342821725234;[GINS4, CDC7]
GO:0006670;sphingosine metabolic process;8.0;0.8933024483968273;0.8216512241984136;9.52844079393514;113.73596156966032;7.292166977892469;0.003806640278016614;0.747921758369865;[SPHK2, SPHK1, SGPP2]
GO:0000209;protein polyubiquitination;10.0;0.7671156992804218;0.7987988615011312;9.223059144383958;155.4032479663248;4.243684138952949;0.005201206855589802;0.6322632160784685;[RNF20, UBE2B, DTX3L, CCNF, SYVN1, ZFP91, FBXL15, LNPEP, FBXL16, ANAPC11, UBE2L3, NPEPPS, ITCH, SPSB1, RNF213, UBE2T, CDC26, TRIM69, FBXL3, ANAPC5, RFFL, SKP2, C18orf25, TRIM32]
GO:0000724;double-strand break repair via homologous recombination;9.0;0.8653626801206646;0.8289219652406215;9.515195567185119;520.6240308586224;5.299736813202263;0.01742481778162994;0.6672694122704188;[YY1, RAD51AP1, POLQ, NIPBL, FEN1, WDR48, RAD51C, RAD51, FBXO18, GINS4, CDC7]
GO:0000722;telomere maintenance via recombination;9.0;0.9326813400603323;0.8625812952104552;9.593432932680852;337.7230221555657;7.212124270218933;0.011303285620559713;0.7650689957573628;[RAD51C, RAD51]
GO:0008612;peptidyl-lysine modification to peptidyl-hypusine;9.0;1.0;0.896240625180289;9.628524252492122;217.569445408162;9.083926447120524;0.007281853538022714;0.8607930461318132;[DOHH]
GO:0090280;positive regulation of calcium ion import;9.0;0.8653626801206646;0.8289219652406215;9.420884887713877;92.69484377077161;6.8867018697843045;0.0031024130010644134;0.7484268790654467;[PDGFRB]
GO:0045954;positive regulation of natural killer cell mediated cytotoxicity;9.0;0.8653626801206646;0.8289219652406215;9.526741558182179;431.31665099041965;6.444869117505266;0.014435780148864921;0.7258315315665724;[LAG3, AP1G1, VAV1]
GO:0008209;androgen metabolic process;6.0;0.8933024483968273;0.7697715367885581;9.4949928598676;78.56989776551285;6.444869117505266;0.002629663769894499;0.6527112189764278;[SGPL1, HSD17B4, HSD17B8, UGT2B7]
GO:0010923;negative regulation of phosphatase activity;9.0;0.7866048967936545;0.7895430735771163;9.362821086759116;265.75489588375854;5.142344639450834;0.008894577201350937;0.659220369185286;[ELL, PPP1R11, ROCK2, PPME1, CD2BP2, PHACTR2, NCKAP1L, PKMYT1]
GO:0051792;medium-chain fatty acid biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;457.16332272744063;7.8311634786251565;0.015300844991408649;0.7967266896635242;[ACOT7]
GO:0015937;coenzyme A biosynthetic process;11.0;1.0;0.9324289523296623;9.628524252492122;6508.605498321825;7.379178354882098;0.2178371686641753;0.8098004765652196;[ACOT7, COASY]
GO:0071422;succinate transmembrane transport;11.0;0.9326813400603323;0.8987696223598284;9.57973408832269;231.32251025672068;7.9853141584524145;0.007742156241549189;0.8407982897480031;[SLC25A10]
GO:0050868;negative regulation of T cell activation;8.0;0.6393367784920305;0.6946683892460153;8.866384200445225;233.2008977034727;5.132682728539097;0.007805024178953029;0.6374856334316459;[ITCH, TWSG1, LAG3, IL4R, CD80, GLMN, CTLA4, PDCD1LG2]
GO:0035924;cellular response to vascular endothelial growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;62.59148538135601;6.599019797332524;0.00209488068703431;0.6605944919115335;[ERN1, MT1G]
GO:0071423;malate transmembrane transport;11.0;0.9326813400603323;0.8987696223598284;9.574457031221845;184.3555933270882;8.390779266560578;0.006170215799395389;0.8615337942327104;[SLC25A10]
GO:0072757;cellular response to camptothecin;7.0;1.0;0.8509193652572005;9.628524252492122;502.88914831670934;8.390779266560578;0.016831247223310163;0.7800242071602487;[RAD51]
GO:0018108;peptidyl-tyrosine phosphorylation;9.0;0.811012628672052;0.801746939516315;9.414950152194063;338.33129968976414;4.530049555519983;0.011323644122215096;0.627907570118429;[PDGFRB, IL5RA, ERLIN2, CLK4, CLK3, CLK1, BCR, ZMYM2, FES, TRIM24, CSK, EPHA1, HBEGF]
GO:0036297;interstrand cross-link repair;8.0;0.8933024483968273;0.8216512241984136;9.541512875502493;183.0506323445446;5.905872616772578;0.006126539929698291;0.6770266002729131;[RAD51AP1, FANCI, DCLRE1C, RAD51, UBE2T]
GO:0006882;cellular zinc ion homeostasis;10.0;1.0;0.9152410118609203;9.628524252492122;329.3407122754199;6.375876246018314;0.011022737252460356;0.7413036195908642;[MT1G]
GO:1902358;sulfate transmembrane transport;8.0;0.8933024483968273;0.8216512241984136;9.4949928598676;123.29733532969695;7.069023426578259;0.0041266508530873195;0.7365101867784198;[SLC25A10]
GO:0046777;protein autophosphorylation;8.0;0.7763722522362496;0.7631861261181248;9.31486669363708;180.75330000196035;4.488806596985934;0.006049650283656873;0.604557778120715;[PDGFRB, MAP3K3, SMG1, CAD, EIF2AK3, VRK2, CLK4, CLK3, CLK1, ERN1, BCR, FES, CAMK4, MKNK2, TRIM24, RIPK1, CSK, EPHA1, MARK2]
GO:1902356;oxaloacetate(2-) transmembrane transport;11.0;0.9326813400603323;0.8987696223598284;9.574457031221845;183.66244614652945;9.083926447120524;0.00614701678705405;0.8969813732811862;[SLC25A10]
GO:0045840;positive regulation of mitotic nuclear division;8.0;0.7140352122741334;0.7320176061370667;9.138976027173417;276.06341799230654;5.75172193694532;0.009239594159256459;0.6691433273378073;[PDGFRB, BECN1, NSFL1C, NIPBL, ESPL1, NUP62, ANAPC5, ANAPC11]
GO:0032526;response to retinoic acid;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;43.78950961223322;5.123113277522946;0.0014655954787213788;0.5522372631225753;[SETX, TBX1, PDGFRB, RXRA, SYNJ1, CTSH]
GO:0071294;cellular response to zinc ion;6.0;1.0;0.8231203125901445;9.628524252492122;78.50383844342444;6.641579411751319;0.0026274528238337297;0.6627709925721352;[ZNF658, MT1G, KCNK3]
GO:0055003;cardiac myofibril assembly;8.0;0.8933024483968273;0.8216512241984136;9.510741216835738;125.46400130584401;6.641579411751319;0.0041991672134361795;0.7146506799819907;[PDGFRB]
GO:0030224;monocyte differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;69.52661413212034;7.004484905440688;0.0023269932051117304;0.6813299963962409;[SP3, MT1G]
GO:0010971;positive regulation of G2/M transition of mitotic cell cycle;9.0;0.8933024483968273;0.8428918493787028;9.52844079393514;355.9636244052406;6.481236761676141;0.011913782162380092;0.7276913745807394;[CCNB1, RAD51C, CDC7, RAB11A, CDC25A]
GO:0006094;gluconeogenesis;7.0;1.0;0.8509193652572005;9.628524252492122;174.6088252776196;5.926926025970411;0.005844000244301424;0.6540226378555745;[PER2, TPI1, G6PC3, SLC25A10, BPGM, ALDOA]
GO:0000707;meiotic DNA recombinase assembly;8.0;0.8259837884571596;0.7879918942285797;9.405380701177911;133.9647452985807;7.697632086000634;0.004483679464700174;0.7686572628545723;[RAD51C, RAD51]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[OXTR, AHCYL1, SUCNR1, ROCK2, DGKA, DEFB1, IQGAP2, CRHR1, RIC8A, HEBP1, C3, ABR, AKAP13, GPR132, GNG2, GNAT2, RGS1, TBXA2R, ADORA3, CCL5, NPPA, OR56B1, CCL19, ECT2, NTSR1, CCR2, PDGFRB, SPHK2, CCL20, SPHK1, GPR55, TSHR, VAV1, SFRP1, GAL, GNAQ, GNB2, NMUR1, CALM1, DAGLB, CALM2, ARHGEF5]
GO:0043552;positive regulation of phosphatidylinositol 3-kinase activity;11.0;0.9326813400603323;0.8987696223598284;9.597752593825367;732.6859750532908;6.375876246018314;0.024522340210466318;0.7584915600596062;[PDGFRB, CCL19]
GO:0060437;lung growth;4.0;1.0;0.75;9.628524252492122;24.192359555962447;8.67846133901236;8.096965026280019E-4;0.6938169164668168;[PDGFRB]
GO:0043161;proteasome-mediated ubiquitin-dependent protein catabolic process;9.0;0.7586651285174919;0.775573189439035;9.310070521373587;348.3589749790861;4.015022244900292;0.01165926138982685;0.6015690495021188;[DERL3, RNF38, CCNF, KIF14, DERL2, BUB1B, PSMB10, PSMA7, ANAPC11, ARNTL, PSMD8, TRIM9, CCNB1, PSMD7, PSMD4, PSMD2, CDC26, PSMB1, UBQLN1, RFFL, SKP2, C18orf25, UBE2I, LRRC29, UBE2B, FBXO18, EDEM1, SYVN1, FBXL15, RAD23A, ERLIN2, FBXL16, KCTD5, SIRT2, DDB1, KBTBD4, NSFL1C, ITCH, SPSB1, PSMA1, KCTD10, TBL1XR1, PSMC1, FBXL3, ANAPC5, MAN1B1, MAD2L1]
GO:0032516;positive regulation of phosphoprotein phosphatase activity;10.0;0.8653626801206646;0.8479223519212526;9.5525383455142;1089.2705050571928;6.832634648514029;0.036456903524454846;0.7646622655359331;[PDGFRB, CALM1, CALM2]
GO:0032355;response to estradiol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;74.25476231829794;4.940791720728991;0.0024852400698459885;0.542913330229313;[PDGFRB, CD4, SFRP1, OXTR, ITGA2, EZH2]
GO:0010863;positive regulation of phospholipase C activity;8.0;0.9326813400603323;0.8413406700301662;9.5544162803384;83.73920694943958;6.139487467954083;0.0028026758962042993;0.6889736746265369;[PDGFRB, GNAQ, GPR55, NMUR1, RASGRP4]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[CMTM7, ERRFI1, COPA, UBE2I, NCF1, CCL20, BUD31, EBI3, FLT3LG, IL6, GAL, IL23A, CCL5, NPPA, FAM3C, CCL19, CHMP6, KCNK3, HBEGF]
GO:0070757;interleukin-35-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;7.379178354882098;0.00101047745553359;0.728290889492758;[EBI3]
GO:0018105;peptidyl-serine phosphorylation;9.0;0.7369933605727446;0.7647373054666613;9.207310787415818;338.73676479787366;4.61801832846594;0.011337214674488616;0.6324062972578516;[SMG1, MAST3, ROCK2, EIF2AK3, CDC7, VRK2, CLK1, ERN1, CCNB1, CAMK4, STK38, MKNK2, STK38L, RIPK1, CAMK1, MARK2]
GO:0050921;positive regulation of chemotaxis;6.0;0.6417349323569144;0.6439877787686017;8.362857879160845;97.3409382187974;4.886724499458715;0.003257913601026301;0.5730276307483924;[PDGFRB, SUCNR1, ITGA2, THBS1, CREB3, IL6, KARS, IL23A, C1QBP, CCL5, NCKAP1L, CCL19, CCR2]
GO:0008360;regulation of cell shape;6.0;0.6763753087927167;0.6613079669865028;8.690254613899192;41.77565885716001;4.6590798152637145;0.0013981937062970905;0.5613858710120996;[VIL1, MKLN1, CFDP1, WDR1, EPB41, FES, WIPF2, LST1, ITGB2, CDC7, VRK2, ALDOA]
GO:1904153;negative regulation of retrograde protein transport, ER to cytosol;12.0;1.0;0.9481203125901445;9.628524252492122;2754.969419366111;7.57984905034425;0.09220634715467685;0.835754145523778;[DERL3, DERL2]
GO:0060981;cell migration involved in coronary angiogenesis;6.0;1.0;0.8231203125901445;9.628524252492122;22.825287336738096;9.777073627680469;7.639418257356832E-4;0.8231203125901445;[PDGFRB]
GO:0042759;long-chain fatty acid biosynthetic process;9.0;0.7980440201809971;0.7952626352707877;9.372590878354922;458.549617088559;6.375876246018314;0.015347243016091356;0.722303232910233;[ACOT7, ELOVL6]
GO:0038171;cannabinoid signaling pathway;6.0;0.8653626801206646;0.7558016526504768;9.4949928598676;26.976932752798508;8.16763571524637;9.028936615729279E-4;0.7408135829017477;[GPR55, DAGLB]
GO:0006589;octopamine biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;737.703660155027;8.67846133901236;0.024690277615198014;0.8400575416471059;[MOXD1]
GO:0006468;protein phosphorylation;7.0;0.5708408884191841;0.6363398094667926;8.175090588534603;177.75756772840523;2.970244267288293;0.005949385820444992;0.5028177952168079;[OXTR, SMG1, MAST3, MAML1, IL5RA, BUB1B, STK19, AKAP13, ZMYM2, RPS6KA2, CFL1, TRIM24, CTSH, PDGFRB, CSNK2A1, KSR1, CAD, VRK2, OXSR1, GFRA2, SPTB, PRKAB1, ERN1, BCR, ILF3, KARS, PDIK1L, FASTKD5, PIK3C3, EPHA1, HBEGF, ROCK2, PKMYT1, RASGRP4, STK3, NUAK1, CCNB1, PABPN1, STK35, CCL5, STK38, MKNK2, STK38L, NCAM1, MBP, RIPK1, CSK, MARK2, MAP3K3, EIF2AK3, CDC7, ERLIN2, CLK4, GTF2H4, CLK3, NFKB1, SETX, CLK1, CDK9, SNRK, PAN3, PTPRA, FES, TNIP2, CAMK4, CCM2, KRAS, CAMK1, CALM1]
GO:0043687;post-translational protein modification;7.0;0.6467165523344657;0.6742776414244334;8.507933057105237;151.15475272427284;3.8799197600437285;0.005059013543235805;0.5493386422205575;[ITIH2, PRKCSH, SERPINA10, CCNF, NEDD8, MSLN, PSMB10, PSMA7, PSMD8, C3, TGOLN2, PSMD7, PSMD4, RBBP5, PSMD2, UBD, PSMB1, SKP2, APOL1, FGA, KLHL25, IGFBP5, FGG, FBXL15, FBXL16, RAB11A, DDB1, IL6, SPSB1, COPS5, PSMA1, PSMC1, RAB13, PSME2, FBXL3]
GO:0000079;regulation of cyclin-dependent protein serine/threonine kinase activity;11.0;0.7866048967936545;0.8257314007264895;9.474373572664863;340.6851601099881;5.181953777545879;0.011402425712143147;0.6974343094988531;[CDKN1A, CCNB1, CDKN2C, CCNE2, CCNF, PKMYT1, CDC25A, CCNJL]
GO:0000086;G2/M transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;43.44612409677276;4.981283082083729;0.0014541026745458175;0.5449840603320351;[CDKN1A, CCNB1, PPME1, CEP70, FBXL15, SKP2, MAPRE1, PKMYT1, CKAP5, CLASP1, CDC25A, PAFAH1B1]
GO:0045590;negative regulation of regulatory T cell differentiation;10.0;0.8933024483968273;0.861892236059334;9.60254876608886;1015.6316661848598;8.67846133901236;0.03399227785805019;0.8590579283277371;[CTLA4]
GO:0009968;negative regulation of signal transduction;6.0;0.43649654099988644;0.5413685830900877;6.680044863788677;140.65047919891595;2.686163805600486;0.0047074449615745265;0.460490854527945;[ERRFI1, ONECUT2, OTUD7B, CIB1, RORA, DUSP14, FLCN, LBH, RGS1, C1QBP, NUP62, WWC3, HIF1AN, DACT1, TLE4, PDGFRB, FGA, IGFBP5, PVRIG, FGG, PLAUR, SENP2, RUNX2, CREB3, SFRP1, TWSG1, RFX4, DDIT4, VDAC2, TAX1BP3, EPHA1, CHMP6, PAFAH1B1, HDAC3, HIST1H2BJ, HDAC1, KLHL12, APCDD1, LILRA2, THBS1, TANK, GLG1, RELA, ARNTL, STK3, PPP2CA, RNF213, SNX25, CCL5, STK38, LMNA, UBQLN1, DVL3, NLRP3, RIPK1, CSK, RFFL, BID, UBE2B, AMBP, EYA2, SYVN1, IFT122, TNFRSF10A, ARHGAP25, NFKBIA, ITCH, NLRP12, IL6, PIK3IP1, CNOT1, BCL3, CALM1, CALM2, TRIM32, EZH2]
GO:0045078;positive regulation of interferon-gamma biosynthetic process;8.0;1.0;0.875;9.628524252492122;834.8798377098682;7.212124270218933;0.027942676825076673;0.7438283705770736;[EBI3]
GO:0030968;endoplasmic reticulum unfolded protein response;5.0;0.8653626801206646;0.7229223519212526;9.387362195675234;54.36536464462378;5.142344639450834;0.0018195598290039001;0.5532207558659172;[ERN1, CREB3, EXTL2, TBL2, CTDSP2, EDEM1, DERL3, LMNA, SYVN1, EIF2AK3, DERL2, TPP1]
GO:0000082;G1/S transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;42.752976916212816;5.142344639450834;0.0014309036622044387;0.5532207558659172;[CDKN1A, CDKN2C, MAX, GMNN, MCM10, CDC7, CDC25A, POLE4, PPP6C, GPR132, CCNE2, POLE2, SKP2, MCM2]
GO:0031497;chromatin assembly;5.0;0.7586651285174919;0.6695735761196662;8.801845679307654;37.85777308927478;6.444869117505266;0.0012670655955142442;0.6198319182472036;[CHAF1B, CHAF1A, GATAD1, H3F3A]
GO:0035338;long-chain fatty-acyl-CoA biosynthetic process;8.0;1.0;0.875;9.628524252492122;500.3176215265477;6.8867018697843045;0.016745180535867314;0.7271862538851576;[ELOVL5, ACSL6, ELOVL6]
GO:0071479;cellular response to ionizing radiation;6.0;0.8933024483968273;0.7697715367885581;9.446202695698167;48.660440229648614;5.602686357784832;0.0016286211429333208;0.6096419534788213;[RAD51AP1, NIPBL, SFRP1, CDKN1A, RAD51, XRCC5, ECT2, ELK1, TANK]
GO:0010833;telomere maintenance via telomere lengthening;8.0;0.9326813400603323;0.8413406700301662;9.590783924509275;185.09737597092234;6.409777797693995;0.00619504259692348;0.7027963346592216;[RAD51, SMG5]
GO:0014911;positive regulation of smooth muscle cell migration;8.0;0.8933024483968273;0.8216512241984136;9.510741216835738;201.77833622021802;6.280566066213989;0.0067533393245778365;0.6961884407023742;[PDGFRB, IGFBP5, ITGA2, CCL5, ATP7A]
GO:0050777;negative regulation of immune response;5.0;0.5193749703860713;0.549928497053956;7.293149336675085;78.83017544275083;4.909539177224887;0.0026383750295169523;0.5413150737011212;[BCR, ABR, CUEDC2, IL4R, AMBP, CTLA4, A2M, CCR2]
GO:0016311;dephosphorylation;5.0;0.6835726970475526;0.6320273603846966;8.32924126836186;24.405590426795786;4.076630054289783;8.168331479794688E-4;0.4987200624199847;[EYA2, SSU72, DUSP28, SSH3, SGPP2, CDC25A, PPM1G, DUSP14, PPP1CB, PTP4A1, POLB, PPP2CA, PPP1CC, DUSP23, PPP6C, G6PC3, SYNJ1, PTPRA, CTDSP2, ACP2]
GO:2000573;positive regulation of DNA biosynthetic process;8.0;0.7980440201809971;0.7740220100904985;9.427853557029971;748.2879117532506;5.618190544320798;0.02504452299098255;0.6623145257091445;[PDGFRB, XRCC5]
GO:0050776;regulation of immune response;4.0;0.37937792944451876;0.4396889647222594;5.635843344046521;22.446924158408432;2.846578861728843;7.512783506617425E-4;0.39557417536826767;[NCKAP1, CUEDC2, SIGLEC9, TFRC, WIPF2, GFI1, C12orf4, CD80, ITGB2, ARPC1A, AP1G1, C1QBP, NPPA, EP300, CTSH, CTLA4, CCR2, HLA-DPA1, IFNAR2, FGA, ACTR2, LAG3, IL4R, FCER1G, PVRIG, FGG, HLA-A, TMEM173, HLA-F, UNC13D, VAV1, BCR, KARS, CD8B, IL23A, ELMO1, PIK3C3, LCP2, ANKRD17, COLEC12, CFH, NLRC4, LILRA2, SUPT6H, TANK, RELA, C2, C3, ABR, HLA-DMB, CCL5, UBQLN1, SLAMF7, NLRP3, LAIR2, NCKAP1L, RIPK1, CSK, CCL19, A2M, HLA-DQA1, CREBBP, AMBP, BTN2A1, XRCC5, PILRB, PILRA, NFKB1, NFKBIA, ITCH, CD4, IL6, COL1A2, ARPC2, POLR3C, FES, TNIP2, HLA-DPB1, MNDA, KRAS, CALM1, HLA-DRB3, C1QC]
GO:0051106;positive regulation of DNA ligation;8.0;0.9326813400603323;0.8413406700301662;9.57973408832269;378.6008333431687;8.16763571524637;0.012671429173367173;0.7926932703116032;[RAD51]
GO:0009062;fatty acid catabolic process;8.0;0.6763753087927167;0.7131876543963583;8.97982883450301;428.6405088203361;5.244474134527214;0.014346212078803813;0.6432026511327102;[ACOT7, ACOX2, CPT2, HSD17B4, ETFB, SLC27A2]
GO:0010571;positive regulation of nuclear cell cycle DNA replication;10.0;0.8436909121759173;0.837086467948879;9.54628615425515;1141.0186722643214;7.9853141584524145;0.038188868110550556;0.8236103492792612;[CDC7]
GO:0006351;transcription, DNA-templated;9.0;0.5708408884191841;0.6816610693898811;8.449869256150476;581.393741231429;1.9872050686257638;0.019458725298619164;0.49786638480429696;[NAB1, GFI1, ARID4A, IKZF1, IKZF2, ELK1, UBE2L3, YY1, SAP130, ZXDC, DPF2, TRIM24, EP300, ZNF326, SOX8, ZNF688, IER5, ZNF564, IER2, GTF2I, TLE4, ZNF441, SAP30BP, CSNK2A1, ZNF282, SND1, ERN1, EID1, ILF3, ZNF93, EWSR1, TBL1XR1, RFX4, HOXB4, TIMELESS, ADNP, ZNF276, ZNF550, ZNF395, ZNF394, MAX, FOXG1, ZNF20, CDCA7, RPAP1, RLF, SUPT6H, GTF2E2, RAD21, ZNF549, HLTF, HIVEP1, ZNF548, HESX1, NLRP3, SUDS3, HIVEP2, ZNF544, TRAPPC2, TFAP2A, ZNF264, DR1, ZNF260, XRCC5, INTS3, PBX3, CNOT10, FLI1, NFKB1, SOX30, CDK9, CNOT6, IRAK1BP1, TFCP2, COPS5, CNOT1, SP1, SP3, ZNF30, MAFF, BCL3, ZNF658, NFE2L3, INTS4, CNOT8, TMEM18, ZNF532, ZNF410, NFE2L1, EZH2, PHF3, SETD5, CIITA, BTG2, ONECUT2, ELL, INTS10, ATF7IP2, HOXC13, CHD1, AFF4, NIPBL, CHAF1B, ZMYM2, LBH, SCML1, C1QBP, ZNF407, NUP62, ZNF768, ZNF525, LRRFIP1, HIF1AN, ZNF485, TSC22D4, KLF12, TBP, KLF13, BUD31, COMMD3, ARNT, BAZ1A, SAFB, PPRC1, ARID1A, ZFX, MED29, SIRT2, MED28, CREB3, ZNF519, TFDP2, ELF4, TFEC, LCOR, VGLL4, ZNF630, ITGB3BP, SMARCD2, HDAC3, ZNF350, HDAC1, WBP2, ZNF69, RELA, ARNTL, SERTAD3, POLR2B, RBBP5, TP53INP2, FAM120B, TP53INP1, TAF1A, POLR2G, GPBP1L1, ASCC3, E2F7, ZNF189, E2F8, TBX1, POLR2J3, ZNF462, CHURC1, EYA2, NFYC, ATAD2, ARID3B, DEK, GRHL1, USF2, GTF2H4, PER2, GFI1B, POLR3C, NFIB, TNIP2, NFIC, MARS, POLR3E, TAF7, MNDA, ZNF696]
GO:0006355;regulation of transcription, DNA-templated;9.0;0.4043225613388953;0.5984019058497367;6.838723401371219;245.35026186902695;1.5478292109445575;0.008211652463856259;0.4753966830094131;[MAML1, GFI1, IKZF1, IKZF2, ELK1, UBE2L3, TIAL1, SAP130, ZXDC, DPF2, TRIM24, SOX8, FBXO5, IER5, IER2, SAP30BP, CSNK2A1, ZNF282, FLT3LG, SND1, MED6, RUNX2, EID1, THAP6, SFRP1, TWSG1, KARS, IL23A, EWSR1, RFX4, BOLA3, HOXB4, TRIM14, ZNF276, ZNF395, ZNF394, FOXG1, ZNF20, CDCA7, RAD21, HLTF, HIVEP1, HESX1, SCAP, HIVEP2, ZNF264, CREBBP, ZNF260, XRCC5, H3F3A, PBX3, EIF2AK3, ERLIN2, FLI1, SOX30, SETX, GOLGB1, PKIA, ZNF30, EZH2, CDKN1C, SETD5, AHCTF1, BTG2, CDKN1A, ELL, ATF7IP2, OTUD7B, HOXC13, AATF, NIPBL, CHAF1B, ZMYM2, SCML1, C1QBP, ZNF485, TSC22D4, NCOA6, SPHK1, COMMD3, BAZ1A, TMEM173, PPRC1, ZFX, MED29, SIRT2, VAV1, MED28, TOX4, GAL, MTF2, TFEC, VGLL4, ARHGEF5, ZNF350, NEDD8, TRAK1, ZNF69, RELA, ARNTL, PPP2CA, SERTAD3, RXRA, UBN1, GPBP1L1, SCAND1, ZNF462, NFYC, ATAD2, GRHL1, GTF2H4, PER2, ITCH, NLRP12, CENPF, GFI1B, HIST3H2A, NFIB, NFIC, CAMK4, MARS, PSMC1, CAMK1, ZNF696, LIMS1, NCF1, NAB1, CD80, GMNN, ARID4A, CIB1, RORA, YY1, ADORA3, WWC3, EP300, SNIP1, ZNF326, ZNF688, FADS1, ZNF564, GTF2I, TLE4, ZNF441, SSU72, ERN1, ILF3, ZNF93, TBL1XR1, TIMELESS, ADNP, PPID, ZNF550, MAX, RLF, SUPT6H, GTF2E2, STK3, BAG3, TPR, ZNF549, ZNF548, DVL3, NLRP3, RIPK1, SUDS3, ZNF544, TRAPPC2, TFAP2A, DR1, UBE2I, CNOT10, NFKB1, CDK9, NFKBIA, CNOT6, IRAK1BP1, IL6, TFCP2, COPS5, CNOT1, SP1, SP3, MAFF, BCL3, ZNF658, NFE2L3, CNOT8, ZNF532, ZNF410, NFE2L1, USP36, CIITA, ONECUT2, ITGB2, DDX41, CHD1, AFF4, FLCN, LBH, ZNF407, NUP62, GATAD1, ZNF768, ZNF525, LRRFIP1, HIF1AN, DACT1, KLF12, TBP, KLF13, PEG3, DTX3L, BUD31, ZFP91, ARNT, SENP2, SAFB, ARID1A, CREB3, ZNF519, TFDP2, SETBP1, ELF4, LCOR, ZNF630, ITGB3BP, MTPN, SMARCD2, HDAC3, HDAC1, WBP2, NLRC4, LRP8, RBBP5, TP53INP2, FAM120B, TP53INP1, TAF1A, ASCC3, ZNF622, E2F7, ZNF189, E2F8, IRX1, TBX1, RNF20, CHURC1, EYA2, FBXL15, ARID3B, DEK, USF2, CD4, POLR3C, TNIP2, TAF7, MNDA, KRAS, TRIM32]
GO:0007202;activation of phospholipase C activity;9.0;1.0;0.896240625180289;9.628524252492122;83.73920694944017;6.444869117505266;0.0028026758962043192;0.7258315315665724;[GNAQ, GPR55, NMUR1, RASGRP4]
GO:0007166;cell surface receptor signaling pathway;5.0;0.43360584258713153;0.507043933154486;5.906854975555195;23.17027026302992;2.006850423521684;7.75488093814194E-4;0.39287143584790796;[NCKAP1, OXTR, NCF1, MAML1, WIPF2, CD80, IL5RA, CIB1, PKD2L1, RORA, TIAL1, GNAT2, ADORA3, NPPA, CFL1, EP300, TLE4, IFNAR2, SEMA6B, PDGFRB, LAG3, IL4R, CSNK2A1, FLT3LG, HLA-A, HLA-F, RUNX2, BCR, SFRP1, TWSG1, KARS, SLC9A6, CD8B, IL23A, DDIT4, ELMO1, PSME2, EPHA1, CD151, DIABLO, EBI3, DTX2, KLHL12, APCDD1, CRHR1, RASGRP4, IL22RA2, RAP1B, SGPL1, BAG3, TSPAN7, TSPAN4, DVL3, NCKAP1L, TSPAN2, RIPK1, MARK2, HLA-DQA1, ATP6V1F, FAM83A, BBS2, CREBBP, UBE2B, BTN2A1, EIF2AK3, IFT122, TNFRSF10A, PILRB, PILRA, NFKB1, SETX, VIL1, NFKBIA, IL6, COL1A2, ARPC2, PTPRA, FES, GNAQ, SDC1, CALM1, HLA-DRB3, CPEB4, CIITA, CDKN1A, SIGLEC9, ITGB3, ITGB2, ARPC1A, NUP62, CASP2, CTLA4, CCR2, DACT1, HLA-DPA1, ACTR2, FCER1G, CAMLG, ITGA2, ROM1, PLAUR, PDCD1LG2, SENP2, GFRA2, YWHAZ, SIRT2, VAV1, DDB1, TAX1BP3, LCP2, LCP1, DAGLB, HBEGF, ROCK2, NOTCH2NL, NEDD9, LILRA2, LRP8, AKAP2, RELA, GNG2, POLR2B, CCL5, MKNK2, IL21R, AP2S1, POLR2G, NCAM1, CSK, CCL19, BID, MAP3K3, CCL20, EYA2, G0S2, LILRB3, TSHR, ITCH, CD4, TNIP2, TSPAN17, HLA-DPB1, CD9, CCM2, MNDA, KRAS, LIMS1]
GO:0042761;very long-chain fatty acid biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;456.7578576193329;7.212124270218933;0.01528727443913519;0.7650689957573628;[ELOVL5, ELOVL6]
GO:0045085;negative regulation of interleukin-2 biosynthetic process;8.0;1.0;0.875;9.628524252492122;836.0204953067102;8.390779266560578;0.027980853608317785;0.8041048419030481;[LAG3]
GO:0042130;negative regulation of T cell proliferation;9.0;0.7763722522362496;0.7844267512984139;9.424925297250882;581.9323154417883;5.734022359845919;0.01947675089275457;0.6894787953221185;[ITCH, TWSG1, CD80, GLMN, CTLA4, PDCD1LG2]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[AVEN, BTG2, CDKN1A, DOCK8, KIF14, CIB1, AATF, UBE2Z, NUP62, CFL1, CASP2, CTSH, SOX8, PDGFRB, TSC22D4, FGA, DFFA, FCER1G, CSNK2A1, SPHK2, SPHK1, FGG, PLAUR, FLT3LG, YWHAZ, DDB1, CREB3, SFRP1, CFDP1, PTRH2, VDAC2, ADNP, EPHA1, PPID, BECN1, HDAC3, HDAC1, NLRC4, THBS1, RELA, BAG3, CCL5, LMNA, NCKAP1L, RIPK1, CCL19, RFFL, SNCB, BID, NTSR1, TBX1, TFAP2A, UBE2B, EYA2, SYVN1, TNFRSF10A, NFKB1, SETX, VIL1, NFKBIA, ITCH, IL6, SON, COPS5, TNIP2, BCL3, KRAS, PDCD1, TRIM32, MAD2L1, CPEB4]
GO:0042098;T cell proliferation;6.0;0.7248374789738407;0.6855390520770648;9.081980546124052;51.294476028837884;6.343086423195323;0.0017167799506538708;0.647506047256038;[CD151, IL23A, ELF4, DOCK8, EBI3, DOCK2]
GO:0043065;positive regulation of apoptotic process;7.0;0.5587538620495764;0.6302962962819887;7.806911820114386;80.91235068524658;3.3969510907807043;0.0027080635610472266;0.5246396020141064;[HRK, UBE2Z, BBC3, FLCN, AKAP13, RPS6KA2, C1QBP, ARL6IP5, CASP2, CTSH, CTLA4, RBM5, PDGFRB, DFFA, FBXO18, ATPIF1, PLAUR, YWHAZ, SIRT2, VAV1, SFRP1, GAL, TFDP2, PTRH2, ARHGEF5, ITGB3BP, PPID, DIABLO, NLRC4, THBS1, STK3, ABR, CCL5, UBD, TP53INP1, TP53BP2, NLRP3, RIPK1, SUDS3, ZNF622, ECT2, BID, NTSR1, TFAP2A, EIF2AK3, G0S2, TNFRSF10A, HSPE1, NLRP12, IL6, FAP, MNDA, PDCD1, SERINC3]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[RAP1B, PDGFRB, FGA, CD4, KARS, CCL20, CCL5, FGG, GPR55, CIB1, CCL19, EPHA1]
GO:0006909;phagocytosis;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;28.437470009997963;5.618190544320798;9.517765291732001E-4;0.610434838299289;[ITGB3, CDC7, TM9SF4, UNC13D]
GO:0010569;regulation of double-strand break repair via homologous recombination;9.0;0.8436909121759173;0.8180860812682478;9.523163736834295;184.48234756552796;6.221725566191056;0.00617445814968456;0.7144199599751273;[RAD51AP1, POLQ, RAD51, FBXO18, USP51, ZNF365]
GO:0030433;ubiquitin-dependent ERAD pathway;10.0;0.9326813400603323;0.8815816818910864;9.600353375525426;603.0491029665483;5.557565922504363;0.02018351076733335;0.6994551915910392;[EDEM1, PSMC1, DERL3, SYVN1, UBQLN1, DERL2, MAN1B1, ERLIN2]
